Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

Redox-Dependent Bone Alkaline Phosphatase Dysfunction Drives Part of the Complex Bone Phenotype in Mice Deficient for Memo1.

Moor MB, Ramakrishnan SK, Legrand F, Dolder S, Siegrist M, Durussel F, Centeno G, Firsov D, Hynes NE, Hofstetter W, Bonny O.

JBMR Plus. 2018 Jul;2(4):195-205. doi: 10.1002/jbm4.10034. Epub 2018 Jan 17.

2.

Renal Memo1 Differentially Regulates the Expression of Vitamin D-Dependent Distal Renal Tubular Calcium Transporters.

Moor MB, Haenzi B, Legrand F, Koesters R, Hynes NE, Bonny O.

Front Physiol. 2018 Jul 9;9:874. doi: 10.3389/fphys.2018.00874. eCollection 2018.

3.

Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition.

Gattelli A, García Solá ME, Roloff TC, Cardiff RD, Kordon EC, Chodosh LA, Hynes NE.

Oncogene. 2018 Jul;37(29):4046-4054. doi: 10.1038/s41388-018-0235-y. Epub 2018 Apr 26.

PMID:
29695833
4.

Expression of the mRNA stability regulator Tristetraprolin is required for lactation maintenance in the mouse mammary gland.

Goddio MV, Gattelli A, Tocci JM, Cuervo LP, Stedile M, Stumpo DJ, Hynes NE, Blackshear PJ, Meiss RP, Kordon EC.

Oncotarget. 2018 Jan 3;9(9):8278-8289. doi: 10.18632/oncotarget.23904. eCollection 2018 Feb 2.

5.

SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.

Moncayo G, Grzmil M, Smirnova T, Zmarz P, Huber RM, Hynx D, Kohler H, Wang Y, Hotz HR, Hynes NE, Keller G, Frank S, Merlo A, Hemmings BA.

Neuro Oncol. 2018 Apr 9;20(5):621-631. doi: 10.1093/neuonc/noy008.

PMID:
29401256
6.

NADPH oxidase-mediated redox signaling promotes oxidative stress resistance and longevity through memo-1 in C. elegans.

Ewald CY, Hourihan JM, Bland MS, Obieglo C, Katic I, Moronetti Mazzeo LE, Alcedo J, Blackwell TK, Hynes NE.

Elife. 2017 Jan 13;6. pii: e19493. doi: 10.7554/eLife.19493.

7.

Serpin E2 promotes breast cancer metastasis by remodeling the tumor matrix and polarizing tumor associated macrophages.

Smirnova T, Bonapace L, MacDonald G, Kondo S, Wyckoff J, Ebersbach H, Fayard B, Doelemeyer A, Coissieux MM, Heideman MR, Bentires-Alj M, Hynes NE.

Oncotarget. 2016 Dec 13;7(50):82289-82304. doi: 10.18632/oncotarget.12927.

8.

Breast Cancer Patients Have Greatly Benefited from the Progress in Molecular Oncology.

Groner BL, Hynes NE.

PLoS Biol. 2016 Sep 29;14(9):e2000314. doi: 10.1371/journal.pbio.2000314. eCollection 2016 Sep.

9.

Memo interacts with c-Src to control Estrogen Receptor alpha sub-cellular localization.

Frei A, MacDonald G, Lund I, Gustafsson JÅ, Hynes NE, Nalvarte I.

Oncotarget. 2016 Aug 30;7(35):56170-56182. doi: 10.18632/oncotarget.10856.

10.

Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models.

Bottos A, Gotthardt D, Gill JW, Gattelli A, Frei A, Tzankov A, Sexl V, Wodnar-Filipowicz A, Hynes NE.

Nat Commun. 2016 Jul 13;7:12258. doi: 10.1038/ncomms12258.

11.

ErbB2: From an EGFR Relative to a Central Target for Cancer Therapy.

Hynes NE.

Cancer Res. 2016 Jul 1;76(13):3659-62. doi: 10.1158/0008-5472.CAN-16-1356. No abstract available.

12.

MEMO1 drives cranial endochondral ossification and palatogenesis.

Van Otterloo E, Feng W, Jones KL, Hynes NE, Clouthier DE, Niswander L, Williams T.

Dev Biol. 2016 Jul 15;415(2):278-295. doi: 10.1016/j.ydbio.2015.12.024. Epub 2015 Dec 31.

13.

Targeting a Novel ER/HOXB7 Signaling Loop in Tamoxifen-Resistant Breast Cancer.

Heideman MR, Frei A, Hynes NE.

Cancer Discov. 2015 Sep;5(9):909-11. doi: 10.1158/2159-8290.CD-15-0871.

14.

Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic niche of breast cancer cells.

Chiovaro F, Martina E, Bottos A, Scherberich A, Hynes NE, Chiquet-Ehrismann R.

Int J Cancer. 2015 Oct 15;137(8):1842-54. doi: 10.1002/ijc.29565. Epub 2015 Apr 29.

15.

Cancer: Staying together on the road to metastasis.

Bottos A, Hynes NE.

Nature. 2014 Oct 16;514(7522):309-10. doi: 10.1038/514309a. No abstract available.

PMID:
25318518
16.

Memo is a copper-dependent redox protein with an essential role in migration and metastasis.

MacDonald G, Nalvarte I, Smirnova T, Vecchi M, Aceto N, Dolemeyer A, Frei A, Lienhard S, Wyckoff J, Hess D, Seebacher J, Keusch JJ, Gut H, Salaun D, Mazzarol G, Disalvatore D, Bentires-Alj M, Di Fiore PP, Badache A, Hynes NE.

Sci Signal. 2014 Jun 10;7(329):ra56. doi: 10.1126/scisignal.2004870.

PMID:
24917593
17.

Memo has a novel role in S1P signaling and is [corrected] crucial for vascular development.

Kondo S, Bottos A, Allegood JC, Masson R, Maurer FG, Genoud C, Kaeser P, Huwiler A, Murakami M, Spiegel S, Hynes NE.

PLoS One. 2014 Apr 8;9(4):e94114. doi: 10.1371/journal.pone.0094114. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e101351.

18.

EGF receptor family: twisting targets for improved cancer therapies.

Burgess AW, Henis YI, Hynes NE, Jovin T, Levitzki A, Pinkas-Kramarski R, Yarden Y.

Growth Factors. 2014 Apr;32(2):74-81. doi: 10.3109/08977194.2014.896355. Epub 2014 Mar 18.

PMID:
24641597
20.

Loss of Memo, a novel FGFR regulator, results in reduced lifespan.

Haenzi B, Bonny O, Masson R, Lienhard S, Dey JH, Kuro-o M, Hynes NE.

FASEB J. 2014 Jan;28(1):327-36. doi: 10.1096/fj.13-228320. Epub 2013 Sep 20.

PMID:
24056085
21.

Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.

Gattelli A, Nalvarte I, Boulay A, Roloff TC, Schreiber M, Carragher N, Macleod KK, Schlederer M, Lienhard S, Kenner L, Torres-Arzayus MI, Hynes NE.

EMBO Mol Med. 2013 Sep;5(9):1335-50. doi: 10.1002/emmm.201302625. Epub 2013 Jul 19.

22.

Signalling change: signal transduction through the decades.

Hynes NE, Ingham PW, Lim WA, Marshall CJ, Massagué J, Pawson T.

Nat Rev Mol Cell Biol. 2013 Jun;14(6):393-8. doi: 10.1038/nrm3581. Epub 2013 May 2. Review.

PMID:
23636498
23.

Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.

Issa A, Gill JW, Heideman MR, Sahin O, Wiemann S, Dey JH, Hynes NE.

Breast Cancer Res. 2013 Jan 23;15(1):R8. doi: 10.1186/bcr3379.

24.

Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth.

Tarkkonen KM, Nilsson EM, Kähkönen TE, Dey JH, Heikkilä JE, Tuomela JM, Liu Q, Hynes NE, Härkönen PL.

PLoS One. 2012;7(11):e49970. doi: 10.1371/journal.pone.0049970. Epub 2012 Nov 21.

25.

Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.

Wöhrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, Guagnano V, Sellers WR, Hofmann F, Kneissel M, Graus Porta D.

J Bone Miner Res. 2013 Apr;28(4):899-911. doi: 10.1002/jbmr.1810.

26.

Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.

Aceto N, Duss S, MacDonald G, Meyer DS, Roloff TC, Hynes NE, Bentires-Alj M.

Breast Cancer Res. 2012 Oct 12;14(5):R131. doi: 10.1186/bcr3329.

27.

The 14-3-3σ tumor suppressor has multiple functions in ErbB2-induced breast cancer.

Hynes NE, Smirnova T.

Cancer Discov. 2012 Jan;2(1):19-22. doi: 10.1158/2159-8290.CD-11-0317.

28.

MHO1, an evolutionarily conserved gene, is synthetic lethal with PLC1; Mho1p has a role in invasive growth.

Schlatter ID, Meira M, Ueberschlag V, Hoepfner D, Movva R, Hynes NE.

PLoS One. 2012;7(3):e32501. doi: 10.1371/journal.pone.0032501. Epub 2012 Mar 7.

29.

FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone.

Wöhrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M, Müller M, Kinzel B, Thuery A, Brueggen J, Hynes NE, Sellers WR, Hofmann F, Graus-Porta D.

J Bone Miner Res. 2011 Oct;26(10):2486-97. doi: 10.1002/jbmr.478.

30.

Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.

Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, Coniglio SJ, Backer JM, Bresnick AR, Condeelis JS, Hynes NE, Segall JE.

Oncogene. 2012 Feb 9;31(6):706-15. doi: 10.1038/onc.2011.275. Epub 2011 Jul 4.

31.

P-Rex1, a guanine exchange factor that is overexpressed in breast cancer, is a convergence node for ErbB and CXCR4 signaling.

Hynes NE, Gattelli A.

Mol Cell. 2011 Jan 7;41(1):5-7. doi: 10.1016/j.molcel.2010.12.024.

32.

Unfavorable drug interactions in targeted breast cancer therapy.

Groner B, Hynes NE.

Cancer Cell. 2010 Nov 16;18(5):401-2. doi: 10.1016/j.ccr.2010.10.027. No abstract available.

33.

Potential for targeting the fibroblast growth factor receptors in breast cancer.

Hynes NE, Dey JH.

Cancer Res. 2010 Jul 1;70(13):5199-202. doi: 10.1158/0008-5472.CAN-10-0918. Epub 2010 Jun 22. Review. Erratum in: Cancer Res. 2010 Oct 1;70(19):7734.

34.

Mammary gland growth factors: roles in normal development and in cancer.

Hynes NE, Watson CJ.

Cold Spring Harb Perspect Biol. 2010 Aug;2(8):a003186. doi: 10.1101/cshperspect.a003186. Epub 2010 Jun 16. Review.

35.

Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.

Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE.

Cancer Res. 2010 May 15;70(10):4151-62. doi: 10.1158/0008-5472.CAN-09-4479. Epub 2010 May 11.

36.

Copine-III interacts with ErbB2 and promotes tumor cell migration.

Heinrich C, Keller C, Boulay A, Vecchi M, Bianchi M, Sack R, Lienhard S, Duss S, Hofsteenge J, Hynes NE.

Oncogene. 2010 Mar 18;29(11):1598-610. doi: 10.1038/onc.2009.456. Epub 2009 Dec 14.

PMID:
20010870
37.

Key signalling nodes in mammary gland development and cancer: Myc.

Hynes NE, Stoelzle T.

Breast Cancer Res. 2009;11(5):210. doi: 10.1186/bcr2406. Review.

38.

c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland.

Stoelzle T, Schwarb P, Trumpp A, Hynes NE.

BMC Biol. 2009 Sep 28;7:63. doi: 10.1186/1741-7007-7-63.

39.

The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression.

Fayard B, Bianchi F, Dey J, Moreno E, Djaffer S, Hynes NE, Monard D.

Cancer Res. 2009 Jul 15;69(14):5690-8. doi: 10.1158/0008-5472.CAN-08-4573. Epub 2009 Jul 7.

40.

Wnt3a regulates proliferation and migration of HUVEC via canonical and non-canonical Wnt signaling pathways.

Samarzija I, Sini P, Schlange T, Macdonald G, Hynes NE.

Biochem Biophys Res Commun. 2009 Aug 28;386(3):449-54. doi: 10.1016/j.bbrc.2009.06.033. Epub 2009 Jun 10.

PMID:
19523451
41.

WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth.

Matsuda Y, Schlange T, Oakeley EJ, Boulay A, Hynes NE.

Breast Cancer Res. 2009;11(3):R32. doi: 10.1186/bcr2317. Epub 2009 May 27.

42.

ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.

Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, Arteaga CL, Segall JE.

Clin Cancer Res. 2009 Jun 1;15(11):3733-9. doi: 10.1158/1078-0432.CCR-08-2163. Epub 2009 May 19.

43.

PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.

Hynes NE, Dey JH.

Cancer Cell. 2009 May 5;15(5):353-5. doi: 10.1016/j.ccr.2009.04.004.

44.

Memo is a cofilin-interacting protein that influences PLCgamma1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration.

Meira M, Masson R, Stagljar I, Lienhard S, Maurer F, Boulay A, Hynes NE.

J Cell Sci. 2009 Mar 15;122(Pt 6):787-97. doi: 10.1242/jcs.032094. Epub 2009 Feb 17.

45.

ErbB receptors and signaling pathways in cancer.

Hynes NE, MacDonald G.

Curr Opin Cell Biol. 2009 Apr;21(2):177-84. doi: 10.1016/j.ceb.2008.12.010. Epub 2009 Feb 7. Review.

PMID:
19208461
46.

The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.

Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M, Wartmann M, Stumm M, Lane HA, Hynes NE.

Cancer Res. 2008 May 15;68(10):3743-51. doi: 10.1158/0008-5472.CAN-07-5100.

47.

Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.

Sini P, Samarzija I, Baffert F, Littlewood-Evans A, Schnell C, Theuer A, Christian S, Boos A, Hess-Stumpp H, Foekens JA, Setyono-Han B, Wood J, Hynes NE.

Cancer Res. 2008 Mar 1;68(5):1581-92. doi: 10.1158/0008-5472.CAN-06-4685.

48.

Memo is homologous to nonheme iron dioxygenases and binds an ErbB2-derived phosphopeptide in its vestigial active site.

Qiu C, Lienhard S, Hynes NE, Badache A, Leahy DJ.

J Biol Chem. 2008 Feb 1;283(5):2734-40. Epub 2007 Nov 28.

49.
50.

Targeting ERBB receptors in cancer.

Hynes NE.

Recent Results Cancer Res. 2007;172:45-57. Review. No abstract available.

PMID:
17607935

Supplemental Content

Loading ...
Support Center